These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12969976)

  • 1. Identification of genes modulated in multiple myeloma using genetically identical twin samples.
    Munshi NC; Hideshima T; Carrasco D; Shammas M; Auclair D; Davies F; Mitsiades N; Mitsiades C; Kim RS; Li C; Rajkumar SV; Fonseca R; Bergsagel L; Chauhan D; Anderson KC
    Blood; 2004 Mar; 103(5):1799-806. PubMed ID: 12969976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.
    Chauhan D; Auclair D; Robinson EK; Hideshima T; Li G; Podar K; Gupta D; Richardson P; Schlossman RL; Krett N; Chen LB; Munshi NC; Anderson KC
    Oncogene; 2002 Feb; 21(9):1346-58. PubMed ID: 11857078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype.
    Yaccoby S
    Clin Cancer Res; 2005 Nov; 11(21):7599-606. PubMed ID: 16278377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development.
    Zhan F; Tian E; Bumm K; Smith R; Barlogie B; Shaughnessy J
    Blood; 2003 Feb; 101(3):1128-40. PubMed ID: 12393520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High heparanase activity in multiple myeloma is associated with elevated microvessel density.
    Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD
    Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of 13q abnormalities in multiple myeloma using immunomagnetically selected plasma cells.
    Fiserová A; Hájek R; Holubová V; Büchler T; Sobotka J; Kovárová R; Musilová R; Bourková L; Buliková A; Mareschová I; Janácková Z; Váñová P; Kuglík P; Vorlícek J; Penka M
    Neoplasma; 2002; 49(5):300-6. PubMed ID: 12458327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
    Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
    Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence.
    Cook JR; Hartke M; Pettay J; Tubbs RR
    J Mol Diagn; 2006 Sep; 8(4):459-65. PubMed ID: 16931586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.
    Ladetto M; Vallet S; Trojan A; Dell'Aquila M; Monitillo L; Rosato R; Santo L; Drandi D; Bertola A; Falco P; Cavallo F; Ricca I; De Marco F; Mantoan B; Bode-Lesniewska B; Pagliano G; Francese R; Rocci A; Astolfi M; Compagno M; Mariani S; Godio L; Marino L; Ruggeri M; Omedè P; Palumbo A; Boccadoro M
    Blood; 2005 Jun; 105(12):4784-91. PubMed ID: 15731178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
    Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
    Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
    Gojo I; Zhang B; Fenton RG
    Clin Cancer Res; 2002 Nov; 8(11):3527-38. PubMed ID: 12429644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.
    Zhan F; Hardin J; Kordsmeier B; Bumm K; Zheng M; Tian E; Sanderson R; Yang Y; Wilson C; Zangari M; Anaissie E; Morris C; Muwalla F; van Rhee F; Fassas A; Crowley J; Tricot G; Barlogie B; Shaughnessy J
    Blood; 2002 Mar; 99(5):1745-57. PubMed ID: 11861292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance.
    Zojer N; Schuster-Kolbe J; Assmann I; Ackermann J; Strasser K; Hübl W; Drach J; Ludwig H
    Br J Haematol; 2002 Jun; 117(4):852-9. PubMed ID: 12060120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.
    Carlo-Stella C; Guidetti A; Di Nicola M; Longoni P; Cleris L; Lavazza C; Milanesi M; Milani R; Carrabba M; Farina L; Formelli F; Gianni AM; Corradini P
    Exp Hematol; 2006 Jun; 34(6):721-7. PubMed ID: 16728276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
    Kara IO; Sahin B; Paydas S; Cetiner S
    Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies.
    Martín P; Santón A; García-Cosío M; Bellas C
    Int J Oncol; 2005 Oct; 27(4):1023-8. PubMed ID: 16142319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic profiling of plasma cell disorders in a clinical setting: integration of microarray and FISH, after CD138 selection of bone marrow.
    Berry NK; Bain NL; Enjeti AK; Rowlings P
    J Clin Pathol; 2014 Jan; 67(1):66-9. PubMed ID: 23969274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.
    Chauhan D; Li G; Auclair D; Hideshima T; Richardson P; Podar K; Mitsiades N; Mitsiades C; Li C; Kim RS; Munshi N; Chen LB; Wong W; Anderson KC
    Blood; 2003 May; 101(9):3606-14. PubMed ID: 12480690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A molecular compendium of genes expressed in multiple myeloma.
    Claudio JO; Masih-Khan E; Tang H; Gonçalves J; Voralia M; Li ZH; Nadeem V; Cukerman E; Francisco-Pabalan O; Liew CC; Woodgett JR; Stewart AK
    Blood; 2002 Sep; 100(6):2175-86. PubMed ID: 12200383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.